Skip to main content

briumvi

Generic: UBLITUXIMAB-XIIY

briumvi: sourced relationships with 1 company · 1 FDA decision.

briumvi evidence translation

What we can confirm

What it means

Source-backed records connect briumvi to TGTX; that link alone does not prove the drug works.

What to watch

Watch for new trials or company disclosures after the FDA record.
BioSniper AIPage evidence connected

Prepared research question

How could briumvi → TGTX affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
TG THERAPEUTICS, INC. (TGTX)
developer · Reported 2023-03-01 · Current development: unknownSource
Relapsing forms of multiple sclerosis (RMS), to include clin…
Approved
FDA Decisions1 records
Approval1 INDICATIONS AND USAGE BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 ).(TGTX)FDA ↗
BLA761238Type 1 - New Molecular EntityStandardIntravenousInjectable

Frequently asked questions

Which companies have sourced relationships with briumvi?

briumvi has dated SEC/FDA relationship records for TG THERAPEUTICS, INC..

What is briumvi's latest FDA decision?

The most recent tracked FDA decision for briumvi is Approval for 1 INDICATIONS AND USAGE BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. BRIUMVI is a CD20-directed cytolytic antibody indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults ( 1 , 14 )., dated December 28, 2022.